MedTrace Logo

Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19

NCT04306705 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2020-03-17

No results posted yet for this study

Summary

Some patients infected with the COVID-19 can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. Tocilizumab was first approved by the U.S. FDA in 2010 for rheumatoid arthritis and might now be used to treat serious COVID-19 patients with lung damage, according to China's National Health Commission updated its treatment guidelines in 7th version.Continuous Renal Replacement Therapy (CRRT) was recommended by China's National Health Commission treatment guidelines in 1st-7th version to control sever COVID-19 patients.

Conditions

Interventions

DRUG

Tocilizumab

Administered as an intravenous infusion.

OTHER

Standard of care

Standard of care therapy per local written policies or guidelines and includes balancing of electrolytes and acid-base, the provision of enteral or parenteral nutrients support, antibiotics therapy, oxygen therapy and noninvasive ventilation.

PROCEDURE

Continuous renal replacement therapy

Catheter insertion site is femoral vein.

Sponsors & Collaborators

  • Hubei Xinhua Hospital

    collaborator OTHER

  • Wuhan No.1 Hospital

    collaborator OTHER

  • Wuhan Central Hospital

    collaborator OTHER

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • SHAOXIAN HU, M.D · Tongji Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-20
Primary Completion
2020-05-30
Completion
2020-06-20
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04306705 on ClinicalTrials.gov